AR032617A1 - Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante - Google Patents

Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante

Info

Publication number
AR032617A1
AR032617A1 ARP010102484A ARP010102484A AR032617A1 AR 032617 A1 AR032617 A1 AR 032617A1 AR P010102484 A ARP010102484 A AR P010102484A AR P010102484 A ARP010102484 A AR P010102484A AR 032617 A1 AR032617 A1 AR 032617A1
Authority
AR
Argentina
Prior art keywords
group
derivatives
biguanida
manufacture
medicinal product
Prior art date
Application number
ARP010102484A
Other languages
English (en)
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850685&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of AR032617A1 publication Critical patent/AR032617A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilizacion de derivados de biguanida de formula general (1), en la cual: los grupos R1 y R2 representan independientemente uno de otro, un átomo de hidrogeno, un grupo alquilo C1-7, un grupo cicloalquilo, un heterociclo, un grupo alquenilo C2-7, un grupo arilo, un grupo arilalquilo, un grupo ariloxialquilo, o un grupo heteroarilo; o R1 y R2 tomados conjuntamente representan un alquileno C2-7 que puede contener uno o varios heteroátomos; y el grupo R3 representa una amina primaria, secundaria o terciaria; o de sus sales farmacéuticamente aceptables para fabricar un medicamento que tiene un efecto cicatrizante, estando dicho medicamento bajo una forma farmacéutica de uso topico.
ARP010102484A 2000-05-26 2001-05-24 Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante AR032617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006798A FR2809310B1 (fr) 2000-05-26 2000-05-26 Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant

Publications (1)

Publication Number Publication Date
AR032617A1 true AR032617A1 (es) 2003-11-19

Family

ID=8850685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102484A AR032617A1 (es) 2000-05-26 2001-05-24 Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante

Country Status (25)

Country Link
US (1) US7199159B2 (es)
EP (1) EP1283708B1 (es)
JP (1) JP4987209B2 (es)
KR (1) KR20030029050A (es)
CN (1) CN100420439C (es)
AR (1) AR032617A1 (es)
AT (1) ATE300942T1 (es)
AU (2) AU2001264011B2 (es)
BG (1) BG65847B1 (es)
BR (1) BRPI0111142C1 (es)
CA (1) CA2410025C (es)
DE (1) DE60112431T2 (es)
DK (1) DK1283708T3 (es)
EC (1) ECSP024359A (es)
EE (1) EE05393B1 (es)
ES (1) ES2244625T3 (es)
FR (1) FR2809310B1 (es)
HU (1) HU229205B1 (es)
MX (1) MXPA02011622A (es)
MY (1) MY137468A (es)
NO (1) NO20025635L (es)
PT (1) PT1283708E (es)
SK (1) SK287249B6 (es)
UA (1) UA76415C2 (es)
WO (1) WO2001091696A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
DE102004022645A1 (de) * 2004-05-07 2005-12-15 Resorba Wundversorgung Gmbh & Co. Kg Bioresorbierbares Material auf Kollagen-Basis
JP4877456B2 (ja) * 2005-04-14 2012-02-15 株式会社 メドレックス ビグアナイド系薬剤を含有するゼリー製剤
KR100926417B1 (ko) * 2007-01-29 2009-11-12 한올제약주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2010025227A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Carrier neutralization/modification in antimicrobial compositions, articles and methods
US9416098B2 (en) * 2010-01-06 2016-08-16 Immunomet Therapeutics Inc. Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
DE212011100215U1 (de) 2011-07-22 2014-03-05 Karel Paul Bouter Ernährungsprodukt, umfassend ein Biguanid
KR101424667B1 (ko) * 2011-08-08 2014-08-04 한올바이오파마주식회사 Ｎ1-고리아민-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US9321742B2 (en) 2011-08-08 2016-04-26 Immunomet Therapeutics Inc. N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
ES2869423T3 (es) * 2011-08-08 2021-10-25 Immunomet Therapeutics Inc Derivados de fenilbiguanida N1-amina cíclica-N5-sustituidos y composición farmacéutica que comprende los mismos
JP6487031B2 (ja) * 2014-04-17 2019-03-20 イミューノメット セラピューティクス インコーポレイテッド グアニジン化合物、及びその用途
CN104262205B (zh) * 2014-09-02 2017-04-12 浙江工业大学 N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
FR3035787B1 (fr) 2015-05-07 2018-08-24 L'oreal Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant
FR3053892A1 (fr) 2016-07-12 2018-01-19 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee de la metformine
CN106822075A (zh) * 2017-03-31 2017-06-13 浙江萧山医院 二甲双胍在促进伤口愈合中的应用
FR3068974B1 (fr) 2017-07-12 2019-08-02 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee d'actif
FR3088542B1 (fr) 2018-11-21 2021-03-19 Waterdiam France Sas Composition cicatrisante comprenant une eau électrolysée
CN110179776B (zh) * 2019-05-31 2022-09-06 宁夏医科大学 二甲双胍的新用途与二甲双胍组合物及组合物的制备方法和应用
CN112494469A (zh) * 2020-07-30 2021-03-16 吴学雷 二甲双胍在制备预防和/或治疗瘢痕的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852584A (en) 1956-05-31 1960-10-26 Us Vitamin Corp Biguanide compositions
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3098008A (en) * 1960-10-05 1963-07-16 Us Vitamin Pharm Corp Method for treatment of dermatological disorders
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3468898A (en) 1966-05-26 1969-09-23 Sterling Drug Inc Bridged bis-biguanides and bis-guanidines
US3996232A (en) * 1970-11-23 1976-12-07 William H. Rorer, Inc. 1,5-Disubstituted biguanides
GB1351025A (en) 1971-08-20 1974-04-24 Aron Md Samuel J Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
US3852353A (en) 1972-12-12 1974-12-03 C Heaphy Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides
US3929999A (en) 1972-12-12 1975-12-30 Clifford John Heaphy Oral hypoglycemic method
US4211770A (en) * 1973-01-16 1980-07-08 The Upjohn Company Treatment of psoriasis intralesionally with N6 -2'-O-dibutyryl cyclic AMP
DE2401450A1 (de) * 1973-01-16 1974-07-18 John James Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
CH602612A5 (es) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
US4163800A (en) * 1977-08-17 1979-08-07 The Procter & Gamble Company Topical composition and treatment of skin lesions therewith
NZ207147A (en) 1983-02-28 1987-08-31 Johnson & Johnson Prod Inc Adhesive bandage containing medicinal substance: pad and base prepared from bulky, non-woven material
FR2552305B1 (fr) * 1983-09-22 1985-12-20 Salkin Andre Composition a pouvoir bactericide eleve contenant un biguanide et une pyrimidine
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
AU1834188A (en) 1987-06-29 1989-01-05 Kendall Company, The Novel medicated dressings
US5246708A (en) 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
SU1560212A1 (ru) * 1988-11-10 1990-04-30 Киевский Медицинский Институт Им.Акад.А.А.Богомольца Способ лечени сифилиса
IT1241994B (it) 1990-08-30 1994-02-02 Idi Farmaceutici Composizione farmaceutica ad effetto cicatrizzante.
IL97771A (en) * 1991-04-04 1996-12-05 Sion Narrow Weaving Dry polymeric material having antimicrobial activity
IT1249711B (it) * 1991-09-30 1995-03-09 Boniscontro E Gazzone S R L Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali.
IT1256111B (it) * 1992-11-23 1995-11-28 Lifegroup Spa Sali dell'acido traumatico ad attivita' cicatrizzante ed antibatterica
JP3493692B2 (ja) 1993-09-09 2004-02-03 三菱マテリアル株式会社 ビスビグアナイド系化合物およびそれを含む殺菌剤
DE19503336C2 (de) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
US5668084A (en) 1995-08-01 1997-09-16 Zeneca Inc. Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US5837255A (en) * 1996-12-10 1998-11-17 Shaman Pharmaceuticals, Inc. Method of reducing blood glucose by administering Harunganin or Vismin
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US5811078A (en) * 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
JP3054758B2 (ja) * 1997-03-27 2000-06-19 小林製薬株式会社 外傷用組成物
CN1197643A (zh) * 1997-04-30 1998-11-04 谢瑞钢 一种创伤油膏
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
NZ505192A (en) * 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
WO2000004875A2 (en) * 1998-07-24 2000-02-03 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2000033829A1 (de) 1998-12-05 2000-06-15 Fresenius Kabi Deutschland Gmbh Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
EP1145717B1 (en) * 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone

Also Published As

Publication number Publication date
HUP0302038A2 (hu) 2003-09-29
HUP0302038A3 (en) 2009-08-28
CA2410025C (fr) 2011-09-06
BRPI0111142C1 (pt) 2021-05-25
EE05393B1 (et) 2011-04-15
NO20025635D0 (no) 2002-11-22
PL359063A1 (en) 2004-08-23
FR2809310B1 (fr) 2004-02-13
NO20025635L (no) 2003-01-21
KR20030029050A (ko) 2003-04-11
DK1283708T3 (da) 2005-12-27
HU229205B1 (en) 2013-09-30
CN100420439C (zh) 2008-09-24
EP1283708B1 (fr) 2005-08-03
AU2001264011B2 (en) 2005-09-15
WO2001091696A2 (fr) 2001-12-06
PT1283708E (pt) 2005-11-30
EP1283708A2 (fr) 2003-02-19
AU6401101A (en) 2001-12-11
FR2809310A1 (fr) 2001-11-30
JP4987209B2 (ja) 2012-07-25
BRPI0111142B1 (pt) 2017-10-24
ECSP024359A (es) 2004-03-23
SK287249B6 (sk) 2010-04-07
US7199159B2 (en) 2007-04-03
CA2410025A1 (fr) 2001-12-06
BR0111142A (pt) 2003-04-08
SK16582002A3 (sk) 2003-04-01
ES2244625T3 (es) 2005-12-16
WO2001091696A3 (fr) 2002-06-06
ATE300942T1 (de) 2005-08-15
MXPA02011622A (es) 2003-03-27
MY137468A (en) 2009-01-30
UA76415C2 (uk) 2006-08-15
DE60112431D1 (de) 2005-09-08
EE200200657A (et) 2004-06-15
US20030187036A1 (en) 2003-10-02
WO2001091696A8 (fr) 2003-01-09
BRPI0111142B8 (pt) 2018-05-02
JP2003534359A (ja) 2003-11-18
BG65847B1 (bg) 2010-03-31
BG107304A (bg) 2003-06-30
CN1635880A (zh) 2005-07-06
DE60112431T2 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
AR032617A1 (es) Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante
AR044719A1 (es) Derivados de fenilo y piridinilo, su uso, un proceso para prepararlos, y medicamentos que los contienen
AR042941A1 (es) Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1)
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
UY27592A1 (es) Nuevo uso
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
PA8551001A1 (es) Nuevos compuestos
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
UY30440A1 (es) Nuevos compuestos
AR053845A1 (es) 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
AR025962A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que los contienen
AR019822A1 (es) Compuestos 2-[trans-(4-aminociclohexil)amino]-purinas-6,9-disustituidas, usos para la fabricacion de medicamentos para el tratamiento de trastornos hiperproliferativos y para el tratamiento de la lesion y degeneracion neuronal, composiciones y composiciones farmaceuticas.
ECSP045278A (es) Compuestos de oxo-azabicíclicos
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
CO4700446A1 (es) Procedimientos para minimizar la perdida osea
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
AR044175A1 (es) Compuestos de cefemo
AR072486A1 (es) Derivados de benzotiadiazinas cicloalquiladas su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
PA8450901A1 (es) Derivados de eritromicina
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
BRPI0409951A (pt) derivados de anilina, sua produção e uso como agentes farmacêuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure